Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aliskiren (fumarate)
2. 1196835-68-3
3. 173334-58-2
4. Aliskirenfumarate
5. (2e)-but-2-enedioic Acid; Bis((2s,4s,5s,7s)-5-amino-n-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide)
6. 5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide Fumarate
7. Chembl1667
8. Mls006010401
9. Hms3264i19
10. Pharmakon1600-01505710
11. Hy-12176b
12. Mfcd27756642
13. Nsc759185
14. Akos025149418
15. Akos037643745
16. Ccg-213555
17. Aliskiren Hemifumarate, >=95% (hplc)
18. As-35076
19. Smr004701404
20. Cs-0134304
21. Sr-05000001949
22. Sr-05000001949-1
23. Benzeneoctanamide, Delta-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphas,gammas,deltas,zetas)-, (2e)-2-butenedioate (2:1)
| Molecular Weight | 667.8 g/mol |
|---|---|
| Molecular Formula | C34H57N3O10 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 21 |
| Exact Mass | 667.40439502 g/mol |
| Monoisotopic Mass | 667.40439502 g/mol |
| Topological Polar Surface Area | 221 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 836 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
A Aliskiren Fumarate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aliskiren Fumarate, including repackagers and relabelers. The FDA regulates Aliskiren Fumarate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aliskiren Fumarate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aliskiren Fumarate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aliskiren Fumarate supplier is an individual or a company that provides Aliskiren Fumarate active pharmaceutical ingredient (API) or Aliskiren Fumarate finished formulations upon request. The Aliskiren Fumarate suppliers may include Aliskiren Fumarate API manufacturers, exporters, distributors and traders.
click here to find a list of Aliskiren Fumarate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Aliskiren Fumarate written confirmation (Aliskiren Fumarate WC) is an official document issued by a regulatory agency to a Aliskiren Fumarate manufacturer, verifying that the manufacturing facility of a Aliskiren Fumarate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Aliskiren Fumarate APIs or Aliskiren Fumarate finished pharmaceutical products to another nation, regulatory agencies frequently require a Aliskiren Fumarate WC (written confirmation) as part of the regulatory process.
click here to find a list of Aliskiren Fumarate suppliers with Written Confirmation (WC) on PharmaCompass.
Aliskiren Fumarate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aliskiren Fumarate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aliskiren Fumarate GMP manufacturer or Aliskiren Fumarate GMP API supplier for your needs.
A Aliskiren Fumarate CoA (Certificate of Analysis) is a formal document that attests to Aliskiren Fumarate's compliance with Aliskiren Fumarate specifications and serves as a tool for batch-level quality control.
Aliskiren Fumarate CoA mostly includes findings from lab analyses of a specific batch. For each Aliskiren Fumarate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aliskiren Fumarate may be tested according to a variety of international standards, such as European Pharmacopoeia (Aliskiren Fumarate EP), Aliskiren Fumarate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aliskiren Fumarate USP).
LOOKING FOR A SUPPLIER?
